LONDON, June 9 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN - News), the London-based neuroscience company, today announced that it intends to seek secondary listings on the AIM Market of the London Stock Exchange and the IEX Market of the Irish Stock Exchange. Amarin will retain its primary listing on NASDAQ and is not seeking any additional capital as part of the listing process. Amarin is already well funded with $33m of cash as at March 31, 2006. Admission to AIM and IEX is expected to occur in mid July.
